The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC.

SkylineDx today announced the publication of new data by Dr. Wesley Yu, et al ²., demonstrating that Merlin CP-GEP identifies ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the National Comprehensive Cancer Network/NCCN updated its 2026 Clinical ...

The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...

ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of ...

National Comprehensive Cancer Network publishes new guidelines for Pediatric Soft Tissue Sarcomas, focused on rhabdomyosarcoma. PLYMOUTH MEETING, Pa., Feb. 17, 2026 /PRNewswire/ -- The National ...

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

The NCCN has updated its guidelines on breast, pancreatic, colon, rectal, non-small cell lung, and other cancers. The National Comprehensive Cancer Network (NCCN) has updated its treatment guidelines ...

Dr. Gerd examines the clinical choices involved in the management of PV, following the directives of NCCN guidelines. Aaron Gerds, MD, MS: The NCCN [National Comprehensive Cancer Network] guidelines ...